US6805865B1
(en)
|
1993-05-27 |
2004-10-19 |
Entremed, Inc. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
US20040248799A1
(en)
*
|
1993-05-27 |
2004-12-09 |
Holaday John W. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
ATE246513T1
(de)
*
|
1993-05-27 |
2003-08-15 |
Entremed Inc |
Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
|
US5504074A
(en)
*
|
1993-08-06 |
1996-04-02 |
Children's Medical Center Corporation |
Estrogenic compounds as anti-angiogenic agents
|
US6908910B2
(en)
|
1993-08-06 |
2005-06-21 |
The Children's Medical Center Corporation |
Estrogenic compounds as anti-mitotic agents
|
US20040214807A1
(en)
*
|
1993-08-06 |
2004-10-28 |
D'amato Robert J. |
Estrogenic compounds as anti-mitotic agents
|
US20010055581A1
(en)
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US6949511B1
(en)
|
1994-04-26 |
2005-09-27 |
The Children's Medical Center Corporation |
Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
|
US5837682A
(en)
*
|
1996-03-08 |
1998-11-17 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
US5945403A
(en)
*
|
1997-05-30 |
1999-08-31 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
US20040265288A1
(en)
*
|
1995-03-08 |
2004-12-30 |
Gilman Michael Z. |
New applications of gene therapy technology
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
DE69629826T2
(de)
*
|
1995-10-23 |
2004-07-01 |
Children's Medical Center Corp., Boston |
Therapeutische antiangiogenische zusammensetzungen und verfahren
|
US5854221A
(en)
*
|
1996-12-12 |
1998-12-29 |
The Children's Medical Center Corporation |
Endothelial cell proliferation inhibitor and method of use
|
US5801146A
(en)
*
|
1996-05-03 |
1998-09-01 |
Abbott Laboratories |
Compound and method for inhibiting angiogenesis
|
JP2000511892A
(ja)
*
|
1996-05-24 |
2000-09-12 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
可溶性ベーターシート形成性ペプチドの合成
|
US6080728A
(en)
*
|
1996-07-16 |
2000-06-27 |
Mixson; A. James |
Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
|
US5700821A
(en)
*
|
1996-07-30 |
1997-12-23 |
University Of Pittsburgh |
Phosphatase inhibitors and methods of use thereof
|
US5801012A
(en)
*
|
1996-09-17 |
1998-09-01 |
Northwestern University |
Methods and compositions for generating angiostatin
|
US6593291B1
(en)
|
1997-02-06 |
2003-07-15 |
Entremed, Inc. |
Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
|
AU6578298A
(en)
|
1997-03-21 |
1998-10-20 |
President And Fellows Of Harvard College |
Antisense inhibition of angiogenin expression
|
US7220557B2
(en)
*
|
1997-04-24 |
2007-05-22 |
Human Genome Sciences, Inc. |
METH1 polynucleotides
|
WO1998049321A2
(en)
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
WO1999006073A1
(en)
*
|
1997-07-31 |
1999-02-11 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Method for the treatment of grafts
|
AU8918898A
(en)
|
1997-08-25 |
1999-03-16 |
Harold Brem |
Prevention of adhesions and excessive scar formation using angiogenesis inhibi tors
|
US20020002294A1
(en)
*
|
1997-09-24 |
2002-01-03 |
D' Amato Robert J. |
Estrogenic compounds as antiangiogenic agents
|
DE69824750T2
(de)
|
1997-10-31 |
2005-07-07 |
Children's Medical Center Corp., Boston |
Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
|
US7229841B2
(en)
*
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
US6407218B1
(en)
*
|
1997-11-10 |
2002-06-18 |
Cytimmune Sciences, Inc. |
Method and compositions for enhancing immune response and for the production of in vitro mabs
|
WO1999026480A1
(en)
*
|
1997-11-20 |
1999-06-03 |
Genetix Pharmaceuticals, Inc. |
Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
RU2229305C2
(ru)
*
|
1998-04-15 |
2004-05-27 |
Лексиген Фармасьютикэлс Корпорейшн |
Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
|
CA2331620A1
(en)
|
1998-05-11 |
1999-11-18 |
The Endowment For Research In Human Biology, Inc. |
Use of neomycin for treating angiogenesis-related diseases
|
US6444431B1
(en)
*
|
1998-05-19 |
2002-09-03 |
Duke University |
Angiostatin receptor
|
US20040022788A1
(en)
|
1998-05-19 |
2004-02-05 |
Moser Tammy L. |
Compositions and methods for promoting or inhibiting angiogenesis
|
US8197430B1
(en)
|
1998-05-22 |
2012-06-12 |
Biopheresis Technologies, Inc. |
Method and system to remove cytokine inhibitor in patients
|
US20030012792A1
(en)
*
|
1998-05-22 |
2003-01-16 |
Holaday John W. |
Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
|
US6620382B1
(en)
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
WO1999065515A2
(en)
*
|
1998-06-15 |
1999-12-23 |
Arch Development Corporation |
Combination of radiotherapy and anti-angiogenic factors
|
US6673341B2
(en)
*
|
1998-07-06 |
2004-01-06 |
Beth Israel Deaconness Medical Center |
Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
|
WO2000002584A2
(en)
|
1998-07-13 |
2000-01-20 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
WO2000003726A1
(en)
*
|
1998-07-14 |
2000-01-27 |
Bristol-Myers Squibb Company |
Lysine binding fragments of angiostatin
|
WO2000010506A2
(en)
*
|
1998-08-20 |
2000-03-02 |
University Of Vermont And State Agriculture College |
Angiogenesis inhibitors and uses thereof
|
US6949081B1
(en)
*
|
1998-08-26 |
2005-09-27 |
Non-Invasive Technology, Inc. |
Sensing and interactive drug delivery
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US7317003B2
(en)
*
|
1998-09-04 |
2008-01-08 |
National University Of Singapore |
Small peptides having anti-angiogenic and endothelial cell inhibition activity
|
US6200954B1
(en)
|
1998-09-04 |
2001-03-13 |
National University Of Singapore |
Small peptides having potent anti-angiogenic activity
|
EP1234585A3
(en)
|
1998-09-04 |
2004-01-21 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6537554B1
(en)
|
1998-09-10 |
2003-03-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
US6248327B1
(en)
|
1998-09-11 |
2001-06-19 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
US7176289B1
(en)
*
|
1998-09-11 |
2007-02-13 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
US6596690B2
(en)
*
|
1998-10-06 |
2003-07-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vasostatin as marrow protectant
|
ES2630278T3
(es)
|
1998-10-16 |
2017-08-21 |
Biogen Ma Inc. |
Conjugados poliméricos de interferón beta-1a y usos de los mismos
|
US6218361B1
(en)
|
1998-11-18 |
2001-04-17 |
Children's Medical Center Corporation |
Treatment of chronic allograft rejection with anti-angiogenic agents
|
US6201104B1
(en)
|
1998-12-04 |
2001-03-13 |
Entremed, Inc. |
Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
|
ATE360062T1
(de)
*
|
1999-02-10 |
2007-05-15 |
Childrens Medical Center |
Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
|
US6465424B1
(en)
*
|
1999-02-17 |
2002-10-15 |
Bristol-Myers Squibb Company |
Anti-angiogenic agent and method for inhibiting angiogenesis
|
US6420345B1
(en)
|
1999-03-01 |
2002-07-16 |
Cell Genesys, Inc. |
Methods and reagents for inhibiting angiogenesis
|
EP1183051A2
(en)
*
|
1999-03-15 |
2002-03-06 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
US6943153B1
(en)
|
1999-03-15 |
2005-09-13 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
ES2209885T3
(es)
*
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc. |
Peptidos insulinotropicos de larga duracion.
|
US7144854B1
(en)
|
1999-09-10 |
2006-12-05 |
Conjuchem, Inc. |
Long lasting anti-angiogenic peptides
|
US6890904B1
(en)
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
CA2382774A1
(en)
*
|
1999-05-25 |
2000-11-30 |
Human Genome Sciences, Inc. |
Meth1 and meth2 polynucleotides and polypeptides
|
US6673843B2
(en)
*
|
1999-06-30 |
2004-01-06 |
Emory University |
Curcumin and curcuminoid inhibition of angiogenesis
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
HUP0202442A3
(en)
*
|
1999-08-09 |
2005-01-28 |
Lexigen Pharmaceuticals Corp L |
Multiple cytokine-antibody complexes
|
US7087592B1
(en)
*
|
1999-08-23 |
2006-08-08 |
Entre Med, Inc. |
Compositions comprising purified 2-methoxyestradiol and methods of producing same
|
US6743428B1
(en)
|
1999-09-15 |
2004-06-01 |
Mogam Biotechnology Research Institute |
Angiogenesis inhibitor
|
US20080241835A1
(en)
*
|
1999-11-01 |
2008-10-02 |
Genentech, Inc. |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
DK2087907T3
(en)
|
1999-11-10 |
2015-01-12 |
Innatus Corp |
Method and system for removing cytokine inhibitor in patients
|
AU2154401A
(en)
|
1999-11-12 |
2001-05-30 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
US6379708B1
(en)
*
|
1999-11-20 |
2002-04-30 |
Cytologic, Llc |
Method for enhancing immune responses in mammals
|
US6723536B2
(en)
|
1999-12-03 |
2004-04-20 |
Entremed, Inc. |
Method of producing and purifying angiostatin
|
EP1218495A2
(en)
*
|
1999-12-03 |
2002-07-03 |
EntreMed, Inc. |
METHOD OF PRODUCING AND PURIFYING ANGIOSTATIN$m(3) PROTEIN
|
US6380253B1
(en)
|
2000-01-05 |
2002-04-30 |
Efa Sciences Llc |
Method of stabilizing and potentiating the action of anti-angiogenic substances
|
CA2398901C
(en)
*
|
2000-02-10 |
2010-11-16 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
ES2269366T3
(es)
|
2000-02-11 |
2007-04-01 |
Merck Patent Gmbh |
Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
|
ES2352175T3
(es)
*
|
2000-02-18 |
2011-02-16 |
New York Medical College |
Composiciones inhibidoras de tumores que comprenden nitroacridinas.
|
US6825167B1
(en)
|
2000-04-03 |
2004-11-30 |
Regents Of The University Of Minnesota |
Genetic modification of endostatin
|
AU7172901A
(en)
*
|
2000-06-29 |
2002-01-14 |
Lexigen Pharm Corp |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
US20050192258A1
(en)
*
|
2000-08-18 |
2005-09-01 |
Agoston Gregory E. |
Antiangiogenic agents
|
US7135581B2
(en)
*
|
2000-08-18 |
2006-11-14 |
Entremed, Inc. |
Antiangiogenic agents
|
US6995278B2
(en)
*
|
2000-08-18 |
2006-02-07 |
Entre Med, Inc. |
Antiangiogenic agents
|
US7160858B2
(en)
*
|
2000-09-01 |
2007-01-09 |
Philadelphia, Health And Education Corporation |
Methods and compositions for inhibiting angiogenesis
|
DE60124927T2
(de)
*
|
2000-09-01 |
2007-09-20 |
Philadelphia Health And Education Corp. |
Verfahren und zusammensetzungen zur inhibition der angiogenese
|
CA2421251A1
(en)
|
2000-09-05 |
2002-03-14 |
Karolinska Innovations Ab |
Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
|
US20030104573A1
(en)
*
|
2000-09-11 |
2003-06-05 |
Shimkets Richard A. |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
US20020159992A1
(en)
*
|
2000-09-29 |
2002-10-31 |
Jack Henkin |
Antiangiogenic polypeptides and methods for inhibiting angiogenesis
|
ATE401337T1
(de)
|
2000-11-28 |
2008-08-15 |
David M Waisman |
Antiangiogene polypeptide
|
ES2290091T3
(es)
*
|
2000-11-30 |
2008-02-16 |
The Children's Medical Center Corporation |
Sintesis de enantiomeros de 4-amino-talidomida.
|
US20040121945A1
(en)
*
|
2000-12-15 |
2004-06-24 |
Hong Liang |
Compositions and methods for inhibiting endothelial cell proliferation
|
CN1455682A
(zh)
*
|
2001-01-05 |
2003-11-12 |
百疗医株式会社 |
包括编码抗-血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物
|
US6632835B2
(en)
|
2001-02-22 |
2003-10-14 |
Nanodesign Inc. |
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
|
DK1366067T3
(da)
*
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
RU2306320C9
(ru)
*
|
2001-05-03 |
2008-01-27 |
Мерк Патент Гмбх |
Рекомбинантное опухолеспецифичное антитело (варианты) и его применение
|
US20030129164A1
(en)
*
|
2001-12-03 |
2003-07-10 |
Flannery John G. |
Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
|
RU2312677C9
(ru)
*
|
2001-12-04 |
2008-03-27 |
Мерк Патент Гмбх |
Иммуноцитокины с модулированной селективностью
|
JP2005526151A
(ja)
|
2002-01-18 |
2005-09-02 |
バイオゲン アイデック エムエー インク. |
生物学的に活性な化合物の結合のための部分を有するポリアルキレングリコール
|
AU2003208913A1
(en)
*
|
2002-01-30 |
2003-09-02 |
Entremed, Inc. |
Non-steroidal analogs of 2-methoxyestradiol
|
US7255986B2
(en)
*
|
2002-01-31 |
2007-08-14 |
The Board Of Trustees Operating Michigan State University |
Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets
|
AU2003211163A1
(en)
|
2002-02-20 |
2003-09-09 |
Regents Of The University Of Minnesota |
Partial peptide mimetics and methods
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
AU2003220091B2
(en)
*
|
2002-03-08 |
2006-02-16 |
Emory University |
Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
|
US7285277B2
(en)
*
|
2002-03-15 |
2007-10-23 |
Mogam Biotechnology Research Institute |
Anticancer agent
|
WO2004037164A2
(en)
*
|
2002-06-21 |
2004-05-06 |
University Of Utah Research Foundation |
Crosslinked compounds and methods of making and using thereof
|
US20040091465A1
(en)
*
|
2002-06-26 |
2004-05-13 |
Zachary Yim |
Therapeutic antiangiogenic compositions and methods
|
US20060142203A1
(en)
*
|
2002-06-26 |
2006-06-29 |
Todd Hembrough |
Compositions and methods comprising protein activated receptor antagonists
|
BR0312692A
(pt)
|
2002-07-15 |
2007-06-26 |
Univ Texas |
anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
|
CA2493341A1
(en)
|
2002-07-23 |
2004-01-29 |
The Regents Of The University Of Michigan |
Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
|
US7189865B2
(en)
*
|
2002-07-23 |
2007-03-13 |
Attenuon, Llc |
Thiomolybdate analogues and uses thereof
|
US8071569B2
(en)
*
|
2002-09-20 |
2011-12-06 |
Mousa Shaker A |
Oxidized heparin fractions and their use in inhibiting angiogenesis
|
US20030153013A1
(en)
*
|
2002-11-07 |
2003-08-14 |
Ruo-Pan Huang |
Antibody-based protein array system
|
AU2003298726A1
(en)
*
|
2002-11-25 |
2004-08-10 |
Attenuon Llc |
Peptides which target tumor and endothelial cells, compositions and uses thereof
|
EP1581164A4
(en)
*
|
2002-12-13 |
2008-03-12 |
Mediomics Llc |
COMPOSITIONS AND METHODS FOR INHIBITING TUMOR GROWTH AND METASTASES
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
DK1572748T3
(da)
*
|
2002-12-17 |
2010-08-23 |
Merck Patent Gmbh |
Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
|
US7407660B2
(en)
*
|
2003-04-16 |
2008-08-05 |
Genentech, Inc. |
Methods and compositions for selective modulation of vascularization
|
EP1624935B1
(en)
|
2003-05-15 |
2016-09-28 |
The University of Utah Research Foundation |
Anti-adhesion composites and methods os use thereof
|
CA2527236A1
(en)
*
|
2003-05-27 |
2004-12-23 |
Attenuon Llc |
Thiotungstate analogues and uses thereof
|
US7371741B2
(en)
*
|
2003-05-28 |
2008-05-13 |
Entremed, Inc. |
Estradiol derivatives and pharmaceutical compositions using same
|
WO2004113361A2
(en)
*
|
2003-06-20 |
2004-12-29 |
The Regents Of The University Of California |
Novel prokineticin receptor isoforms and methods of use
|
US20070020234A1
(en)
*
|
2003-07-07 |
2007-01-25 |
Vande Woude George F |
Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
|
US20050250694A1
(en)
*
|
2003-10-10 |
2005-11-10 |
Ma Jian-Xing |
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
|
US20050143300A1
(en)
*
|
2003-10-10 |
2005-06-30 |
Ma Jian-Xing |
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
|
WO2005065121A2
(en)
*
|
2003-12-02 |
2005-07-21 |
Cytimmune Sciences, Inc. |
Methods and compositions for the production of monoclonal antibodies
|
US20100330143A1
(en)
|
2003-12-04 |
2010-12-30 |
University Of Utah Research Foundation |
Modified macromolecules and methods of making and using thereof
|
JP4993465B2
(ja)
*
|
2003-12-04 |
2012-08-08 |
ユニバーシティ オブ ユタ リサーチ ファウンデーション |
変性された高分子ならびにその製造方法および使用方法
|
US20050130897A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Ma Jian-Xing |
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
|
MXPA06008293A
(es)
|
2004-01-22 |
2007-06-11 |
Univ Miami |
Formulaciones topicas de coenzima q10 y metodos de uso.
|
CN1960825A
(zh)
*
|
2004-01-28 |
2007-05-09 |
细胞免疫科学公司 |
官能化胶态金属组合物和方法
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
EP1729784A1
(en)
*
|
2004-02-23 |
2006-12-13 |
Attenuon, LLC |
Formulations of thiomolybdate or thiotungstate compounds and uses thereof
|
AU2005222934B2
(en)
|
2004-03-12 |
2010-06-17 |
Entremed, Inc. |
Antiangiogenic agents
|
US20070004689A1
(en)
*
|
2004-03-12 |
2007-01-04 |
Agoston Gregory E |
Antiangiogenic agents
|
AU2005236075A1
(en)
*
|
2004-04-26 |
2005-11-03 |
Children's Medical Center Corporation |
Platelet biomarkers for the detection of disease
|
CA2565215C
(en)
*
|
2004-04-30 |
2014-04-15 |
Biopheresis Technologies, Inc. |
Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
|
US8618054B2
(en)
*
|
2004-05-05 |
2013-12-31 |
Valorisation-Rechereche Société en Commandite |
Interleukin-1 receptor antagonists, compositions, and methods of treatment
|
CA2576971A1
(en)
*
|
2004-08-20 |
2006-03-02 |
Entremed, Inc. |
Compositions and methods comprising proteinase activated receptor antagonists
|
EP1827462A4
(en)
*
|
2004-11-24 |
2012-01-04 |
Therakine Ltd |
IMPLANT FOR INTRAOCULAR DRUG DELIVERY
|
WO2006058298A2
(en)
*
|
2004-11-29 |
2006-06-01 |
Entremed, Inc. |
A method of administering anti-angiogenic agents and a method of treating disease using same
|
AU2006210627B2
(en)
|
2005-02-01 |
2011-05-19 |
Attenuon, Llc |
Acid addition salts of Ac-PHSCN-NH2
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
AU2006264567A1
(en)
|
2005-05-05 |
2007-01-11 |
Valorisation Hsj, Societe En Commandite |
Cytokine receptor modulators and uses thereof
|
US20070065514A1
(en)
*
|
2005-09-22 |
2007-03-22 |
Howell Mark D |
Method for enhancing immune responses in mammals
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
US20070185069A1
(en)
*
|
2005-11-14 |
2007-08-09 |
Plum Stacy M |
Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
US20070176403A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Dennis Calderone |
Air adjustable seat
|
JP2009530388A
(ja)
*
|
2006-03-20 |
2009-08-27 |
エントレメッド インコーポレイテッド |
2−メトキシエストラジオールの疾患修飾性抗関節炎活性
|
US8747870B2
(en)
|
2006-04-20 |
2014-06-10 |
University Of Utah Research Foundation |
Polymeric compositions and methods of making and using thereof
|
CA2649915A1
(en)
*
|
2006-04-20 |
2007-11-01 |
University Of Utah Research Foundation |
Polymeric compositions and methods of making and using thereof
|
CN101511876A
(zh)
*
|
2006-07-11 |
2009-08-19 |
犹他大学研究基金会 |
用亲电子基团修饰的大分子及其制备和使用方法
|
US20080075690A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Mark Douglas Howell |
Method for enhancing immune responses in mammals
|
US20080234243A1
(en)
*
|
2007-01-31 |
2008-09-25 |
Lavallee Theresa M |
Method of treating amyloidosis mediated diseases
|
US20080287341A1
(en)
*
|
2007-05-18 |
2008-11-20 |
Danyang Chen |
Treatment of vascular abnormalities using nanoparticles
|
EP2200932A4
(en)
*
|
2007-09-21 |
2014-09-10 |
Cytimmune Sciences Inc |
NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS
|
US20110014118A1
(en)
*
|
2007-09-21 |
2011-01-20 |
Lawrence Tamarkin |
Nanotherapeutic colloidal metal compositions and methods
|
CA2706700A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Cytimmune Sciences, Inc. |
Compositions and methods for generating antibodies
|
JP5809415B2
(ja)
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ,インコーポレーテッド |
抗vegf抗体の組成物および方法
|
PT2279254T
(pt)
|
2008-04-15 |
2017-09-04 |
Protiva Biotherapeutics Inc |
Novas formulações lipídicas para entrega de ácido nucleico
|
WO2010005527A1
(en)
|
2008-06-30 |
2010-01-14 |
Angioblast Systems, Inc. |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
WO2010051531A1
(en)
|
2008-10-31 |
2010-05-06 |
University Of Louisville Reserch Foundation, Inc. |
Olfactory epithelial-derived stem cells and methods of use therefor
|
CA2787054A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
CA2795698A1
(en)
*
|
2010-03-05 |
2011-09-09 |
Angstrom Pharmaceuticals, Inc. |
Modulation of intracellular signaling
|
US10865383B2
(en)
|
2011-07-12 |
2020-12-15 |
Lineage Cell Therapeutics, Inc. |
Methods and formulations for orthopedic cell therapy
|
US8921533B2
(en)
|
2011-07-25 |
2014-12-30 |
Chromatin Technologies |
Glycosylated valproic acid analogs and uses thereof
|
EP2788020A4
(en)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
EP2628748A1
(en)
|
2012-02-14 |
2013-08-21 |
Szilak Laboratories Bioinformatics & Molecule-Design Ltd. |
Angiostatin chimeras and uses thereof
|
TWI702955B
(zh)
|
2012-05-15 |
2020-09-01 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
KR20230078823A
(ko)
|
2012-12-13 |
2023-06-02 |
이뮤노메딕스, 인코오포레이티드 |
개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
CA2900176A1
(en)
|
2013-02-13 |
2014-08-21 |
Cartiheal (2009) Ltd |
Solid substrates for mitigating or preventing cell and tissue adhesion and vascularization
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10064940B2
(en)
|
2013-12-11 |
2018-09-04 |
Siva Therapeutics Inc. |
Multifunctional radiation delivery apparatus and method
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
MY187898A
(en)
|
2015-03-02 |
2021-10-27 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
JP7379795B2
(ja)
|
2016-04-27 |
2023-11-15 |
イミューノメディクス、インコーポレイテッド |
チェックポイント阻害薬に再発/耐性を示す腫瘍を治療するための抗Trop-2-SN-38抗体薬物複合体の効果
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
|
EP3746151B1
(en)
|
2018-02-28 |
2024-04-24 |
Plas-Free Ltd. |
Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
|
EP4190911A4
(en)
*
|
2020-08-20 |
2024-03-13 |
Talengen Int Ltd |
METHOD AND DRUGS FOR TUMOR TREATMENT
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|